Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breast cancer subtypes may hold clues to survival and cost

NCT ID NCT07856225

Knowledge-focused Sponsor: Fundación Santa Fe de Bogota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 02, 2026 · Last updated Oct 02, 2026

Summary

Researchers in Bogota, Colombia, are reviewing the medical records of 370 women treated for breast cancer between 2014 and 2024. They want to see how different molecular subtypes of the disease relate to survival, recurrence, treatment response, and side effects. The study also looks at how the COVID-19 pandemic and health insurance type affected outcomes, and estimates the direct medical costs of care. No treatments are assigned or changed; the team only studies existing records.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
The findings could help doctors in Colombia match treatments to breast cancer subtypes and plan care budgets more accurately.
What could go wrong
This is a look back at old records from one hospital, so it cannot prove cause and effect, and the results may not apply to other clinics or countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 370 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women 18 years or older with histologically confirmed breast cancer and a documented molecular subtype who were treated and/or followed at Hospital Universitario Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024, identified through institutional clinical databases, pathology reports and oncology follow-up records.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years with a histopathologically confirmed diagnosis of breast cancer. * Treated at Fundación Santa Fe de Bogotá between January 1, 2014 and December 31, 2024. * Available record of the tumor molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched or triple-negative), determined by immunohistochemistry and/or in situ hybridization. Exclusion Criteria: * Metastatic tumors from another primary site involving the breast (for example, breast metastases from another primary tumor). * Lesions of uncertain malignant potential or in situ tumors. * Incomplete or missing information on molecular subtype, treatment received or clinical outcomes. * Oncology follow-up outside the institution without adequate traceability of clinical outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm COVID-19 HER2 positive breast carcinoma hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms HER2-positive breast cancer Hormone receptor-positive breast cancer Triple negative breast neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario Fundación Santa Fe de Bogotá

    RECRUITING

    Bogotá, Bogota D.C., Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.